JP2019006815A5 - - Google Patents

Download PDF

Info

Publication number
JP2019006815A5
JP2019006815A5 JP2018173770A JP2018173770A JP2019006815A5 JP 2019006815 A5 JP2019006815 A5 JP 2019006815A5 JP 2018173770 A JP2018173770 A JP 2018173770A JP 2018173770 A JP2018173770 A JP 2018173770A JP 2019006815 A5 JP2019006815 A5 JP 2019006815A5
Authority
JP
Japan
Prior art keywords
lipid
mole
peg
chol
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018173770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019006815A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2019006815A publication Critical patent/JP2019006815A/ja
Publication of JP2019006815A5 publication Critical patent/JP2019006815A5/ja
Pending legal-status Critical Current

Links

JP2018173770A 2013-03-13 2018-09-18 修飾されたドセタキセルリポソーム製剤 Pending JP2019006815A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779902P 2013-03-13 2013-03-13
US61/779,902 2013-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017177620A Division JP2017214433A (ja) 2013-03-13 2017-09-15 修飾されたドセタキセルリポソーム製剤

Publications (2)

Publication Number Publication Date
JP2019006815A JP2019006815A (ja) 2019-01-17
JP2019006815A5 true JP2019006815A5 (https=) 2019-07-25

Family

ID=50686145

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502155A Expired - Fee Related JP6294456B2 (ja) 2013-03-13 2014-03-13 修飾されたドセタキセルリポソーム製剤
JP2017177620A Pending JP2017214433A (ja) 2013-03-13 2017-09-15 修飾されたドセタキセルリポソーム製剤
JP2018173770A Pending JP2019006815A (ja) 2013-03-13 2018-09-18 修飾されたドセタキセルリポソーム製剤

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2016502155A Expired - Fee Related JP6294456B2 (ja) 2013-03-13 2014-03-13 修飾されたドセタキセルリポソーム製剤
JP2017177620A Pending JP2017214433A (ja) 2013-03-13 2017-09-15 修飾されたドセタキセルリポソーム製剤

Country Status (8)

Country Link
US (1) US20140271822A1 (https=)
EP (1) EP2968145A1 (https=)
JP (3) JP6294456B2 (https=)
CN (1) CN105188675A (https=)
BR (1) BR112015022819A8 (https=)
CA (1) CA2903255C (https=)
MX (1) MX2015012201A (https=)
WO (1) WO2014160392A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105188675A (zh) * 2013-03-13 2015-12-23 马林克罗特有限公司 经修饰多西他赛脂质体制剂
CN104622810B (zh) * 2015-02-15 2018-06-08 中国药科大学 一种稳定型难溶性抗肿瘤药物脂质体及其制备方法
US20160250177A1 (en) * 2015-02-17 2016-09-01 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
CN107613962B (zh) 2015-04-02 2021-02-09 纽约州立大学研究基金会 血清稳定组合物和用于光触发的材料释放的方法
US20180344644A1 (en) * 2015-09-21 2018-12-06 Mallinckrodt Llc Improved stability of liposome formulations and uses thereof
WO2017120586A1 (en) * 2016-01-07 2017-07-13 Western University Of Health Sciences Formulations for treating bladder cancer
SG11201807148RA (en) * 2016-03-16 2018-09-27 Merrimack Pharmaceuticals Inc Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome compositions
CA3016383A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions
US20190298681A1 (en) * 2016-03-16 2019-10-03 Merrimack Pharmaceuticals, Inc. Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics
IL264842B (en) * 2016-08-18 2022-08-01 Troy Bremer Delivery of urea to cells of the macula and retina using liposome constructs
CN107951861B (zh) * 2016-10-17 2020-12-01 南京绿叶制药有限公司 一种脂质纳米粒膜材料组合物
WO2018106980A1 (en) * 2016-12-08 2018-06-14 Mallinckrodt Llc Liposomal elinafide formulations and uses thereof
US20190008987A1 (en) 2017-07-07 2019-01-10 Drexel University Voltage-Activated Therapeutic, Diagnostic, And/Or Theranostic Constructs
CN110496103B (zh) * 2018-05-18 2022-05-10 上海维洱生物医药科技有限公司 一种多西他赛棕榈酸酯脂质体及其制备方法
JP7482487B2 (ja) * 2018-09-13 2024-05-14 タイワン リポソーム カンパニー リミテッド 鎮静薬を含む徐放性医薬組成物およびその使用
TWI767149B (zh) * 2018-10-17 2022-06-11 台灣微脂體股份有限公司 含有免疫調節劑的緩釋藥物組合物及其用途
US20220265679A1 (en) * 2019-08-09 2022-08-25 Tesorx Pharma, Llc Proliposomal testosterone undecanoate formulations
CN110571005B (zh) * 2019-09-27 2021-01-01 广西科技大学 一种固定化金属离子-磁性脂质体及其制备方法和应用
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114588279B (zh) * 2022-03-31 2023-10-20 重庆医科大学附属第二医院 一种多功能纳米分子探针及其制备方法和其作为视网膜母细胞瘤诊疗制剂的应用
WO2025124498A1 (zh) * 2023-12-13 2025-06-19 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物的脂质体及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994005282A1 (en) 1992-09-04 1994-03-17 The Scripps Research Institute Water soluble taxol derivatives
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US6107332A (en) 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
WO2005079185A2 (en) * 2003-09-02 2005-09-01 Board Of Regents, The University Of Texas System Neutral liposome-encapsulated compounds and methods of making and using thereof
ATE401057T1 (de) * 2004-10-08 2008-08-15 Alza Corp Verfahren zur einführung eines lipid-verknüpften teils in eine vorgeformte lipidanordnung mit mikrowellen
MX2007013200A (es) * 2005-04-22 2008-03-24 Johnson & Johnson Composicion de inmunoliposoma para el direccionamiento hacia un receptor de la celula her2.
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
EP3415151A1 (en) * 2008-05-23 2018-12-19 The University of British Columbia Modified drugs for use in liposomal nanoparticles
CN102038641B (zh) * 2009-10-26 2013-04-17 石药集团中奇制药技术(石家庄)有限公司 一种外层经亲水聚合物修饰的脂质体药物的制备方法
US20120231066A1 (en) * 2011-01-24 2012-09-13 Henry John Smith Multi-drug liposomes to treat tumors
JP2014503582A (ja) * 2011-01-28 2014-02-13 コーニンクレッカ フィリップス エヌ ヴェ 親水性プロドラッグの局所放出用担体
CN102188713A (zh) * 2011-05-09 2011-09-21 中山大学 一种肝靶向药物组合物及其制备方法
CN105188675A (zh) * 2013-03-13 2015-12-23 马林克罗特有限公司 经修饰多西他赛脂质体制剂

Similar Documents

Publication Publication Date Title
JP2019006815A5 (https=)
US8932627B2 (en) Liposomal compositions of glucocorticoid and glucocorticoid derivatives
JP2021522163A5 (https=)
JP2020510072A5 (https=)
US20170273906A1 (en) Targeted liposomes encapsulating iron complexes and their uses
RU2014120216A (ru) Комбинационные липосомальные композиции для лечения рака
CN101991538B (zh) 一种含tpgs的脂质体组合物及其应用
PT2508170E (pt) Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
CA2739822A1 (en) Liposomal systems comprising sphingomyelin
US12370214B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
WO2005117878A1 (ja) イリノテカン製剤
JP7770367B2 (ja) 徐放性麻酔剤組成物およびその調製方法
JP2016513651A5 (https=)
JP2018527335A5 (https=)
JP6230538B2 (ja) 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法
TWI767133B (zh) 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途
JP4833836B2 (ja) リポソーム製剤
JP2024526791A (ja) リポソーム製剤の調製方法
EP1793805A1 (en) Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions
AU2016233143B2 (en) Methods for the treatment of bladder cancer
JP2024526800A (ja) Bcl阻害剤のリポソーム製剤
HK40043569A (en) Inhalable liposomal sustained release composition for use in treating pulmonary diseases
RU2019132446A (ru) Соединения и композиции для внутриклеточной доставки терапевтических агентов